John B. Sanfilippo & Son, Inc.
NASDAQ:JBSSPackaged Foods
+$0.62 today
- Market cap
- $715.76M
- Beta
- 0.35
- P/E (TTM)
- 13.7
- EPS (TTM)
- $5.72
- Dividend yield
- 5.11%
Volume 0.15M
Average 0.11M
JBSS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
John B. Sanfilippo & Son, Inc.NASDAQ: JBSS
Research & Development · Q3 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q3 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-26 | 0 | — |
| FY2024 | 2024-06-27 | 0 | — |
| FY2023 | 2023-06-29 | 0 | — |
| FY2022 | 2022-06-30 | 0 | — |
| FY2021 | 2021-06-24 | 0 | — |
Research & Development vs competitors
How JBSS compares with its peers on the latest reported figures
- JBSS's LTM Mar 2026 research & development of $0 is the 2nd highest of the 5 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for JBSS, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $252.6K | — | — | 1.9% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Jul 2026 | $0 | — | — | 0.0% | |
| LTM Jul 2026 | $0 | — | — | 0.0% | |
| LTM Feb 2026 | $0 | — | +10.3% | 0.0% | |
| Peer median (excluding JBSS) | $0 | — | +10.3% | 0.0% | |
Competitors are the stored peer set for JBSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 858.48M | 955.87M | 999.69M | 1.07B | 1.11B |
| Cost of Revenue | 673.5M | 756.24M | 788.06M | 852.64M | 903.78M |
| Gross Profit | 184.99M | 199.63M | 211.63M | 214.14M | 203.47M |
| Gross Margin | 21.5% | 20.9% | 21.2% | 20.1% | 18.4% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 101.21M | 115.89M | 122.73M | 132.48M | 120.61M |
| Operating Expenses | 99.81M | 112.19M | 121.41M | 128.95M | 118.76M |
| Depreciation & Amortization | 18.31M | 19.71M | 22.14M | 26.6M | 31.47M |
| EBITDA | 99.57M | 103.33M | 109.65M | 109.09M | 112.89M |
| EBITDA Margin | 11.6% | 10.8% | 11.0% | 10.2% | 10.2% |
| Operating Income | 85.18M | 87.44M | 90.22M | 85.19M | 84.71M |
| Operating Margin | 9.9% | 9.1% | 9.0% | 8.0% | 7.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.44M | 1.92M | 2.16M | 2.55M | 3.55M |
| Other Income / Expenses | (5.36M) | (5.74M) | (4.87M) | (5.25M) | (6.85M) |
| Income Before Tax | 79.82M | 81.7M | 85.35M | 79.94M | 77.87M |
| Pre-Tax Margin | 9.3% | 8.5% | 8.5% | 7.5% | 7.0% |
| Income Tax Expense | 20.08M | 19.91M | 22.49M | 19.69M | 18.93M |
| Net Income | 59.74M | 61.79M | 62.86M | 60.25M | 58.93M |
| Net Margin | 7.0% | 6.5% | 6.3% | 5.6% | 5.3% |
| EPS (Basic) | 5.19 | 5.36 | 5.43 | 5.19 | 5.06 |
| EPS (Diluted) | 5.17 | 5.33 | 5.40 | 5.15 | 5.03 |
| Weighted Avg Shares | 11.5M | 11.54M | 11.58M | 11.62M | 11.66M |
| Weighted Avg Shares (Diluted) | 11.56M | 11.59M | 11.64M | 11.69M | 11.72M |
John B. Sanfilippo & Son, Inc.
NASDAQ:JBSS
Intrinsic Alpha fair value
Locked
Current Price
$61.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.